BioAge Labs CFO sells 27,000 shares ($531.8K) across 4 transactions; retains 22,408 shares post-sale
CFO Dov Goldstein sold 27.0K shares over four separate transactions on 2026-01-13 at prices ranging from $18.43 to $21.08, generating $531,827.69 in aggregate proceeds and reducing his holdings by 54.6%. The sales occurred during a period of significant stock appreciation—the stock has risen 71.9% over 30 days and 315.2% over 90 days, and currently trades at $21.51, near its 52-week high of $22.92. BioAge Labs remains unprofitable on a full-year basis with net income of $-20,171,000.00 against quarterly revenue of only $2,054,000.00, indicating the company is pre-revenue or in early commercialization with substantial operating losses. The combination of material share reduction, elevated stock price relative to historical range, and persistent large-scale losses creates a notable signal about capital deployment priorities at a cash-constrained biotech firm.